carbidopa-levodopa
Phase 3Small molecule
Neurocrine Biosciencescarbidopa-levodopa is one of 131 small molecule programs targeting Stroke. It is currently in Phase 3.
4
Indications
16
Total Trials
3
Active Trials
130
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
147 competitors in Stroke
#DrugCompanyPhaseTrials
1carbidopa-levodopa
Neurocrine BiosciencesPhase 3
Polycap
NNorthern California Institute of Research and Education
Phase 3
Zometa
PfizerPreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic pain2 trials
Anhedonia2 trials
Parkinson's Disease2 trials
Amyotrophic Lateral Sclerosis1 trial
8 more indications
Single Dose1 trial
Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study
Completed·—·Phase 4·NCT00590122·20 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for carbidopa-levodopa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company